Acute toxicity of boron nitride nanotubes in-vitro and in-vivo.
Authors
Kodali V; Roberts J; Wolfarth M; Eye T; Barger M; Roach K; Smith K; Schwegler-Berry D; Porter D; Erdely A
Source
nanoTOX 2016, Proceedings of the 8th International Nanotoxicology Congress, June 1-4, 2016, Boston, Massachusetts. Boston: MA: International Nanotoxicology Congress, 2016 Jun; :162
Boron nitride nanotubes (BNNTs) are an emerging engineered nanomaterial that has attracted significant attention due to its superior electrical, chemical, and thermal properties. As the number of applications grow, occupational exposures will likely increase. Since its toxicity is largely unknown, we performed acute in-vitro and in-vivo exposure studies with 13-23 nm diameter x 0.6-1.6 microm length BNNTs. THP-1 wild-type and NLRP3 knockout human monocytic cells were exposed to 0-100 microg/ml and male C57BL/6 mice were exposed by pharyngeal aspiration to 4 or 40 microg BNNTs and sacrificed 4 and 24 h post-exposure. The multi-walled carbon nanotube-7 (MWCNT-7) served as a particle control. In-vitro, BNNT induced a dose-dependent increase in cytotoxicity. This was confirmed in vivo by increased bronchoalveolar lavage levels of lactate dehydrogenase, a measure of lung cytotoxicity. In vitro, lysosomal destabilization, likely a result of particle uptake, was evident by acridine orange staining. Subsequent NLRP3 inflammasome activation was demonstrated by a dose dependent increase in IL-1beta protein as well as cathepsin B and caspase 1 activity. Toxicity, and IL-1beta production were attenuated in exposed NLRP3 knockout THP-1 cells. In-vivo, elevated pulmonary IL-1beta confirmed in vitro findings. Consistent with suspected BNNT-induced inflammation, pulmonary neutrophil influx and inflammatory markers (Il6, Ccl2, Ccl22, Cxcl2) increased in a dose-dependent manner. In general, toxicity induced by BNNTs was less in comparison to MWCNT-7. Taken together, these results demonstrate that BNNTs induce inflammation in vitro and in vivo in part due to NLRP3 inflammasome activation and sub-chronic in vivo studies are warranted.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.